International Collaboration to Ensure Equitable Access to Vaccines for COVID‐19: The ACT‐Accelerator and the COVAX Facility

  title={International Collaboration to Ensure Equitable Access to Vaccines for COVID‐19: The ACT‐Accelerator and the COVAX Facility},
  author={Mark Eccleston-Turner and Harry Upton},
  journal={The Milbank Quarterly},
  pages={426 - 449}
Policy Points Equitable access to a COVID‐19 vaccine in all countries remains a key policy objective, but experience of previous pandemics suggests access will be limited in developing countries, despite the rapid development of three successful vaccine candidates. The COVAX Facility seeks to address this important issue, but the prevalence of vaccine nationalism threatens to limit the ability of the facility to meet both its funding targets and its ambitious goals for vaccine procurement. A… 
Access to COVID-19 vaccines and testing in Africa: the importance of COVAX - Nigeria as a case study.
Since pandemic declaration, the vulnerability of countries with serious economic challenges and limited health resources became evident. This vulnerability has been put to the test once again with
COVID-19 Vaccination in Lower-Middle Income Countries: National Stakeholder Views on Challenges, Barriers, and Potential Solutions
The findings suggest that COVID-19 vaccination is different from previous vaccination programs, and therefore, policymakers have to expand the EPI structure and also take a systematic and collaborative approach to plan and effectively rollout the vaccines.
COVID-19 Pandemic and Equal Access to Vaccines
This article analyzes, as regards the worldwide distribution of anti-COVID-19 vaccines, the various ways the principle of equity has been construed and applied or even overlooked.
Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
It is argued that there is now a clear need for concerted global multilateral action to recognise the complementarities of specific models and to provide a pathway for collaboration in attaining global equitable access to vaccines.
COVAX, vaccine donations and the politics of global vaccine inequity
COVAX’s pivot from global vaccine procurement mechanism to dose-sharing hub can be seen as a “ win-win-win” solution for COVAX itself, for donor countries (who could claim success by having access to more doses), and for the pharmaceutical industry (maintaining the status quo on intellectual property rights and protecting their commercial interests).
Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?
The review comprehensively summarizes the history of vaccines, mainly focusing on vaccines for SARS-CoV-2, and connects relevant topics, including measurement of vaccines efficacy against Sars-Cov-2 and its variants, associated challenges, and limitations, as hurdles in global vaccination are kept forth.
Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
It is indicated that including the principles of equitable access throughout vaccine research and development, procurement, scale-up and distribution processes can support equitable access for LMICs.
Pharmaceutical Industry’s Engagement in the Global Equitable Distribution of COVID-19 Vaccines: Corporate Social Responsibility of EUL Vaccine Developers
Whether the pharmaceutical industry is acting according to the principles of corporate social responsibility (CSR) during the pandemic is examined to help understand the current COVID-19 vaccine distribution inequality and propose that pharmaceutical companies re-examine their roles and social responsibilities.


The Procurement of a COVID-19 Vaccine in Developing Countries: Lessons from the 2009-H1N1 Pandemic
A vaccine is key to the COVID-19 global response strategy. However, it is not yet clear how any COVID-19 vaccine will or ought to be distributed, despite the significant issues of fairness, equity,
The Equitable Distribution of COVID-19 Therapeutics and Vaccines.
Here is a proposal for global cooperation to ensure equitable distribution of vaccines and therapies for COViD-19, with a common global interest.
The goal of COVAX is to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification by the end of 2021.
Global plan seeks to promote vaccine equity, spread risks.
The World Health Organization and other international organizations have set up a system to accelerate and equitably distribute vaccines, the COVID-19 Vaccines Global Access Facility, to avoid a scenario of limited supplies.
Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges
  • L. Hessel
  • Political Science
    Influenza and other respiratory viruses
  • 2009
An influenza pandemic will place an enormous strain on the world’s vaccine production, distribution and administration systems, and manufacturers have successfully developed antigen‐sparing strategies and significantly increased production capacity, with further growth planned assuming ongoing rising demand for seasonal vaccines.
Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: Lessons from 2009-H1N1
Using procurement during 2009-H1N1 as a case study, this paper examines the methods of procurement utilised by states in order to determine if the procurement tools available to developing states are sufficient to procure adequate levels of pandemic influenza vaccines.
Developing a SARS-CoV-2 Vaccine at Warp Speed.
The coronavirus disease 2019 (COVID-19) pandemic has unleashed major and substantial changes in the provision of health care, including public health policy and the practice of medicine, and in the ways most individuals live their lives, and it is clear the only way to provide effective herd immunity is with a safe and effective vaccine.
Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases.
Synthetic vaccinology and platform manufacturing are important innovations that can speed the initial vaccine immunogen design and vaccine development process, and shorten the time needed for manufacturing and initial regulatory approval to begin phase 1 testing.
Facilitating Access to a COVID-19 Vaccine through Global Health Law
It will be crucial to develop legal commitments to ensure vaccine access prior to a scientific breakthrough, analyzing the legal barriers that impede global access and the global health law reforms necessary to facilitate global solidarity.